Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
TransCode Therapeutics develops RNA-based oncology therapeutics with a proprietary delivery platform targeting undruggable genetic markers in cancer. Its focus includes metastatic tumors, utilizing modular design and imaging-guided delivery to enhance targeting, stability, and efficacy. The company’s lead candidate, TTX-MC138, targets microRNA-10b to inhibit metastasis across multiple cancers, advancing through clinical trials to offer precision, potentially transformative cancer treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.